HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to ...

Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for ...

An established cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) showed potential for ...

In a report released today, Carter Gould from Barclays maintained a Buy rating on Cytokinetics (CYTK – Research Report), with a price ...

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

“The Muscle: a Study in Biology and Pathology” (Exp. Sc. Fr., Paris, 1950). Schapira, G., Coursaget, J., Dreyfus, J. C., and Schapira, Mme F., 2nd International ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

Purpose-driven marketing elevates brand-consumer relationships beyond transactional interactions. By linking brand values ...

The biological needs of plants and animals affect their cells' protein content, but the story goes deeper than that.

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...